A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports this week in Science Translational Medicine. The findings support further development of the drug candidate for treating and preventing current coronavirus infections and potential future epidemic outbreaks.
Coronaviruses are a genetically diverse family of viruses that infect birds and mammals, with most coronavirus strains limited to infecting only certain hosts. Human coronaviruses, for example, cause up to 30 percent of common colds.
In the last 15 years, however, coronaviruses have demonstrated their ability to jump into new species. Zoonotic (animal) coronaviruses have infected humans, causing severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), severe diseases with high mortality rates ranging from 10 percent for SARS to 40 percent for MERS. The MERS-coronavirus continues to cause new infections in the Middle East.
“There’s a real concern that the MERS coronavirus could escape broadly when millions of people visit Saudi Arabia for the Hajj,” said Mark Denison, M.D., Craig-Weaver Professor of Pediatrics and professor of Pathology, Microbiology and Immunology at Vanderbilt University School of Medicine.
But to date, there has been no effective antiviral drug for any known coronavirus, Denison noted.
Denison and his team at Vanderbilt have studied the basic biology of coronaviruses for more than 20 years. In an effort to find chemical tools that would allow them to probe viral replication, graduate student Brett Case screened a series of compounds selected and provided by Gilead Sciences.
Case demonstrated that one of the compounds was highly active against coronaviruses in cultured cells. The finding was a surprise, Denison said, because compounds in the same class (nucleoside analogs) have normally failed to inhibit coronavirus replication.
The compound, called GS-5734, is currently in clinical development for treatment of Ebola virus disease.
Denison’s longtime collaborator Ralph Baric, Ph.D., at the University of North Carolina and his team demonstrated that GS-5734 inhibits SARS-coronavirus and MERS-coronavirus replication in multiple in vitro systems, including cultures of primary human airway epithelial cells, which are the cells infected by respiratory coronaviruses.
The researchers also showed that GS-5734 was effective against a circulating human coronavirus, bat coronaviruses, and bat coronaviruses that are considered “prepandemic” because they can infect cultured human cells.
Using a mouse model of SARS, the investigators demonstrated that both prophylactic (before infection) and early therapeutic (soon after infection) administration of GS-5734 reduced viral load in the lungs and improved respiratory functions.
“This compound shows broad activity against a variety of human and animal coronaviruses and represents an exciting potential therapeutic for a family of viruses prone to emergence from animal reservoirs,” Denison said.
Denison and his team at Vanderbilt will continue to use the compound “as a probe to try to understand the biology of the virus, how and why this drug works, and to identify new targets for inhibiting coronaviruses,” he said.
“This is an exciting example of how pursuing fundamental research to understand the mechanisms of virus replication and pathogenesis can lead to an important compound with therapeutic potential.”
The Latest on: Coronaviruses
- New Antiviral Drug Inhibits Epidemic SARS, MERS and Animal Coronaviruseson November 2, 2019 at 5:00 pm
A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports this week in Science ...
- Bats are the Major Reservoir of Coronaviruses Worldwideon November 2, 2019 at 5:00 pm
Results of a five-year study in 20 countries on three continents have found that bats harbor a large diversity of coronaviruses (CoV), the family of viruses that cause Severe Acute Respiratory ...
- Matchmaking between virus and hoston June 27, 2019 at 5:00 pm
Coronaviruses not only include the deadly respiratory viruses, such as SARS and MERS, but also viruses that usually cause mild respiratory tract infections. However, mild coronavirus infections can ...
- SARS-Associated Coronaviruson June 12, 2019 at 5:00 pm
(pages 1995–2005), Tsang et al. (pages 1977–1985), and Lee et al. (pages 1986–1994). Although human coronaviruses cause up to 30 percent of colds, they rarely cause lower respiratory tract disease. In ...
- An unexpected mode of action for an antibodyon January 31, 2019 at 8:07 am
Currently, no vaccines or specific treatments are available for any of the six coronaviruses that can infect humans. Some of these coronaviruses cause only common-cold like symptoms, but others ...
- An unexpected mode of action for an antibodyon January 31, 2019 at 8:02 am
Studies of human monoclonal antibodies isolated from survivors of coronavirus-induced severe acute respiratory syndrome (SARS) or Middle-East respiratory syndrome (MERS) are unveiling surprising ...
- Origin and evolution of pathogenic coronaviruseson December 10, 2018 at 4:41 am
Both viruses likely originated in bats, and genetically diverse coronaviruses that are related to SARS-CoV and MERS-CoV were discovered in bats worldwide. In this Review, we summarize the current ...
- Bovine-like coronaviruses in domestic and wild ruminantson December 1, 2018 at 4:00 pm
To send this article to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and ...
- Potential To Crush Coronaviruseson March 22, 2018 at 1:23 pm
RNA viruses called coronaviruses have long been known to cause pneumonia and the common cold. These viruses have been found to be able to jump between human and animal hosts. Lethal outbreaks of ...
- Broad spectrum antiviral drug may inhibit more coronaviruses: studyon March 6, 2018 at 6:06 pm
WASHINGTON, March 6 (Xinhua) -- American researchers reported a promising experimental broad spectrum antiviral drug against coronaviruses in this week's mBio, a journal of American Society of ...
via Google News and Bing News